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heart disease ntirely would only add a few years to the lives 
of bodies that are prey to many other diseases as well as to 
the multiple systemic degradations and failures that are part 
of the aging process. Yet the kind of deep understanding of 
human biochemistry that would lead to a complete cure of 
heart disease could not exist in a vacuum: such deep under- 
sumding would undoubtedly ead to cures, preventatives, or
powerful therapies for many other diseases and conditions. 
Furthermore, some studies, such as those on telomerase and 
glycosylation, seem to offer insight into the aging process itself. 
It is on this general-systems question that our conclusions 
,ire dearly the most speculative. Yet, we believe that it is quite 
possible that the next 50 years will see the introduction of 
therapies that will allow people to five significantly onger lives. 
SUMMARY 
The fiftieth anniversary of the ACC and the end of the 
twentieth century are arbitrary points in time, yet they seem 
to coincide with a true watershed. The last 50 years have 
brought a rush of new techniques and understandings that 
have, for the first time, given cardiovascular specialists real 
tools to prevent and fight cardiovascular disease. Only now, 
for the first time, has science begun to understand exactly 
what happens when plaque forms in an artery, when heart 
muscle fibers cross-link and weaken, when an atrial chamber 
fibrillates, and when heart muscle cells die en masse after a 
heart attack. We are beginning to track down the actual 
chemical, mechanical, and electrical pathways by which the 
heart is damaged or dies. When we can interfere with those 
pathways and stop the chain of events, we will have defeated 
heart disease. 
Imagination is rapid, but progress is often both uncertain 
and slow because of the many constraints of cost, regulation, 
and time needed to test and evaluate new developments. Yet 
we can now foresee a future in which medical science 
might actually defeat cardiovascular disease the way it has 
defeated polio, smallpox, and other serious scourges of 
the past. 
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Technology is ineluctably human. It could be said that our 
ability to produce technology is what defines us as humans. 
It is who we are. 
Technology is driven by our desires. So, it is not surpris- 
ing that every new development prompts debates about 
ethics, morality, and philosophy. These debates can be 
boiled down to the questions, '%Vho are we, as humans?" 
arid WVhat do we really want?" 
These questions became specially vivid during the cri- 
tiques and discussions around early versions of this report. 
For instance, some new developments raise the possibility of 
extending the human life span beyond its current limits. 
That possibility is not at all a consensus goal among physicians 
or cardiovascular specialists. Some consider it morally suspect. 
The moral, ethical, legal, and social issues raised by these 
new technologies include the following: 
GENOMICS 
Privacy. I f  it becomes possible by mapping the SNPs in 
your genome to determine not only which diseases and 
syndromes you have now but also which ones you are likely 
to have in the future, to whom should this information be 
made available? Your insurors? Your employer? Your pro- 
spective mployers? Your school? Your spouse? Your dating 
partners? Your friends and neighbors? Government agen- 
des? 
Wherever we draw the bright line of privacy, how should 
we enforce it? What should we do about he black market in 
genomic information that will inevitably develop? 
Do we have a right to not know our own future? If  you 
could know your own health future decades in advance, 
would you want to? Will we be able to refuse the knowledge, 
or will it be forced on us? 
Cost. Already, one of the greatest problems that physicians 
report in getting patients to comply with their drug regi- 
mens is that the patients imply cannot afford the drugs. 
Many older people, especially those who are living on fixed 
incomes and facing multiple health problems, have to 
choose between eating and taking a full course of their heart 
medicine. The new drugs derived from genomic informa- 
tion may greatly exacerbate this problem. Some will be 
inexpensive. Many will be expensive but cheaper than the 
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surgeries and other treatments hat they replace. Others will 
be expensive by any measure, reflecting their enormous 
research costs. These costs could create an ever-widening 
gap between those who can afford powerftd new medicines 
and those who cannot. 
REPLACEMENT HEARTS 
Swine hearts. Online discussions with a variety of author- 
ities in what is kosher under the dietary laws of Judaism and 
under the laws of Islam show little concern that replacing a
human heart with a swine heart would be religiously 
forbidden. Some do not consider surgery to be equivalent to 
eating. Most cite traditions that suspend such laws when 
necessary to save a life. 
Neo-organs. To grow a heart muscle, you start with a 
donated human egg cell, substitute genetic material from a 
cell taken from the person for whom you are growing the 
heart muscle, and grow the resulting embryo in a laboratory 
dish to the 100-cell blastocyst stage. Then, you strip off 
the outer layer of cells, disaggregate he inner cell mass, 
and grow it into a colony of embryonic stem ceils. Finally, 
you stimulate them chemically to differentiate as myo- 
cytes, heart muscle cells. 
Until you strip off the outer layer of the blastocyst, he 
embryo is a human clone. Implanted in a uterus, it could grow 
into a full human being. To some, this means that it is a full 
human being and should not be used for any purpose, no 
matter how noble. To others, it is only a potential human being 
and does not become a human unless it is implanted in a 
uterus. Much the same process has occurred without 
comment for decades in fertility clinics doing in-vitro 
fertilizations (a number of embryos are created; when one 
is successfully implanted, the others are destroyed). Yet 
the idea of using embryonic stem cells has already created 
controversy and is currently under congressional ban in 
any laboratory receiving federal funds. Some experiment- 
ers believe, however, that neo-organs can be grown from 
more mature cells--fibroblasts--thus avoiding this par- 
ticular problem. 
PATIENT DATA 
Turning medical records into digital data makes copying 
them far easier and arouses privacy concerns, much the same 
as the creation of genomic data. The main protection for 
smart cards is that they require special readers. The main 
protection for CD-ROM cards and cards with personal 
identification numbers for Web sites is the patient's physical 
possession of them. 
LIFE EXTENSION 
The idea of extending people's lives beyond what seems to 
be their natural limit is not supported by any ethical 
consensus. Many physicians consider their goal to be curing 
disease, easing pain and disability, and avoiding early 
death--not extending life. 
If methods of extending life prove to be feasible, then it is 
likely that they WIU be considered medicaBy unnecessary, like 
cosmetic surgery, and so will not be covered. This means that 
only the financiaUy well-offwill live longer--a situation that is 
sure to provoke a great deal of ethical debate. 
These ethical concerns are likely to slow research in certahl 
areas, delay the adoption of some techniques for general use, 
and help mold the eventual shape of the technologies that 
come into use over the next decades. Technology is not some 
neutral force set apart from people; it is an expression of human 
desires and world views through scientific means. 
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Because this article is more likely than most articles in the 
Journal of the American College of Cardiology to be read by 
members of the media and other noncardiologists, we 
provide definitions of a few of the technical terms used: 
Angiogenesis: growth of new arteries; incardiology, anglo- 
genesis typically refers to the use of new drugs, such as vascular 
endothelial growth factor (VEGF) to promote the growth of 
new cardiac arteries that supply the heart muscles with blood. 
Angioplasty:. various techniques to re-open arteries that have 
been narrowed orclosed by arterial plaque. 
Apoptosis: cell self-destruction. 
Catheters: long, wirelike instruments typically inserted 
into large arteries to do work in the heart or the arteries. 
